TUESDAY, DECEMBER 10, 2020
SESSION 1
12:00
Opening remarks and presentation of Barry-Wainberg DART Achievement AwardRaymond F. Schinazi
Emory University, USA
12:55
Evidence for non-CD4+ T cell reservoirs in HIV persistenceMario Stevenson
University of Miami, USA
Oral Abstract Session
13:50
Long-term SHIV suppression using AAV delivery of monoclonal antibodiesJosé M. Martinez-Navio
University of Miami, USA
14:00
The in vitro antiviral activity of the anti-hepatitis C virus drugs daclatasvir and sofosbuvir against SARS-CoV-2Carolina Q. Sacramento
Fiocruz, Brazil
14:10
Factors associated with readmission following COVID-19 hospitalizationElizabeth Verna
Columbia University, USA
SESSION 2: Industry session (non-CME): Advancements in long-acting injectable HIV treatments
14:25
Progress in long-acting agents for HIV treatment and PrEP: ViiV Healthcare program (non-CME)William Spreen
ViiV Healthcare, USA
14:45
Recent progress in development of long-acting injectables for HIV treatment (non-CME)Stephanie Barrett
Merck, USA
15:05
Lenacapavir (GS-6207): First-in-class long-acting HIV capsid inhibitor (non-CME)Martin Rhee
Gilead Sciences, USA
15:40
Concluding remarksRaymond F. Schinazi
Emory University, USA
CME Accreditation:
The Emory University School of Medicine designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credits. This accreditation is for both days of the conference (HIV DART: December 10, 2020 and Respi DART: December 17, 2020). Physicians should claim only the credit commensurate with the extent of their participation in the activity. Fees associated with obtaining credits incude $35 USD for both days of the meeting.
The Emory University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Please submit your certification request through this link. Please contact us at info@ihorizonsed.com for additional information.